Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 7/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 7/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 7/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448974 | 0.86 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL2451623 | 0.84 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2448167 | 0.76 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2446613 | 0.74 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12332316 | 0.74 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL2452937 | 0.71 | ABCC9 (0.47) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL2449004 | 0.71 | GLA (0.43) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL12332318 | 0.70 | ABCC9 (0.44) | ABCC9ABCC8KCNJ11KCNJ8MAPT | |
| SCHEMBL2448648 | 0.70 | ABCC9 (0.43) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL2446037 | 0.68 | LIPG (0.44) | ABCC9ABCC8KCNJ11KCNJ8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237891-B1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | claimed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | claimed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | claimed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | claimed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | claimed |
| EP-1237891-B1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-1237891-B1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | disclosed |
| US-6706720-B2 | TREATMENT OF ARRHYTHMIA; INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | disclosed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | ABCC9 297/4885ABCC8 292/4885KCNJ11 21/4885 |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | ABCC9 297/4885ABCC8 292/4885KCNJ11 21/4885 |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNQ5, KCNQ2 | ABCC9 246/4885ABCC8 268/4885KCNJ11 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.